In the April–June 2014 edition of Corporate Disputes, Group Vice President and Global Practice Leader Dr. Gregory Bell and other industry experts discuss pharma and biotech patent litigation.
A look at Chinese courts’ new approach to IP damages
In this Law360 article, Fei Deng, Hong Qiao, and Yi Cheng examine the trend of Chinese courts toward awarding larger non-statutory damage awards in IP cases....